Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fujian
Clinical trial register · China

Clinical Trials in Fujian, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche3 Merck Sharp & Dohme LLC2 Sinovac Biotech Co., Ltd2 Fujian Medical University Union Hospital2 Fujian Medical University2
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Fujian

36 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fujian Medical University
Phase 2
28
Fujian
2026-10-10
Recruiting
Yongquan Shi
Phase 4
448
Zhengzhou, Xi'an, Wenzhou, Beijing, Chongqing, Foshan, Fujian, Guangzhou
2026-10-01
Not yet open
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
NCT07750041Unresectable Advanced or Metastatic Colorectal Cancer
DrugsSYS6090·Folfoxiri·MFOLFOX6·Regorafenib
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
260
Fujian
2026-08-30
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Not yet open
Sinovac Biotech Co., Ltd
Phase 3
6,000
Hefei, Fujian, Henan, Hubei, Sichuan
2026-05
Not yet open
Fujian Medical University Union Hospital
Observational
3,000
Fujian
2026-04-28
Recruiting
RemeGen Co., Ltd.
Phase 1/2
326
Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing
2026-04-27
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
Fujian Medical University
Not applicable
55
Fujian
2025-07-20
Recruiting
BrosMed Medical Co., Ltd
Not applicable
198
Fujian
2025-06-27
Recruiting
Bayer
Phase 1
148
Xuhui, Fujian, Wuhan
2025-02-28
Recruiting
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Recruiting
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Not yet open
Peking University Third Hospital
Early Phase 1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Active, closed
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Fujian Cancer Hospital
Phase 2
37
Fujian
2023-08-01
Active, closed
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Beijing, Fujian, Guangdong, Henan, Hubei, Shanxi, Shengyang, Tianjin
2022-12-07
Recruiting
National Natural Science Foundation of China
Observational
1,600
Fujian, Shanhai, Shenzhencun
2022-12-01
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds
NCT05984628Skin Wound, Scar, Hypertrophic
Fujian Medical University Union Hospital
Not applicable
88
Fujian
2021-10-20
Active, closed
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou, Beijing, Chongqing, Fujian, Gansu, Guangdong, Guangxi, Guizhou
2020-07-08
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Active, closed
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Recruiting
The Chinese Familial Alzheimer's Network
NCT03657732Alzheimer Disease, Familial Alzheimer Disease (FAD)
Capital Medical University
Observational
40,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2005-01-10
Recruiting
China Cognition and Aging Study
NCT03653156Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
Capital Medical University
Observational
100,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2000-01-01
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/fujian

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Fujian.

How many clinical trials are recruiting in Fujian?

23 of the 36 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 6 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fujian), 36 studies
PhaseStudiesRecruitingShare
Phase 29625%
Phase 39525%
Observational6416.7%
Not applicable338.3%
Phase 1328.3%
Phase 1/2328.3%
Early Phase 1102.8%
Phase 2/3102.8%
Phase 4112.8%

Most active sponsors

Lead sponsors with the most studies (Fujian)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche30
Capital Medical University22
Fujian Medical University21
Fujian Medical University Union Hospital21
Merck Sharp & Dohme LLC22
Sinovac Biotech Co., Ltd21
Adcentrx Therapeutics10
AstraZeneca10
Bayer11
Beijing InnoCare Pharma Tech Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.